Platelet transfusion is associated with 90-day and 1-year mortality for adult patients requiring veno-arterial extracorporeal membrane oxygenation.
blood component production
platelet transfusion
transfusion - surgery
transfusion medicine
transfusion strategy
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
18
09
2020
received:
17
06
2020
accepted:
21
09
2020
pubmed:
21
11
2020
medline:
29
6
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
Studies examining one-year mortality respecting component blood transfusion are sparse. We hypothesize that component blood product transfusions are negatively associated with 90-day and 1-year survival for all patients requiring veno-arterial (VA) or veno-venous (VV) ECMO. This was an IRB-approved retrospective cohort analysis of 676 consecutive patients requiring ECMO at the University of Pittsburgh between 2005 and 2016. Patients were analysed both as an entire cohort and as two subsets with respect to ECMO modality (VA vs. VV). Additional data collected and analysed included patient characteristics, laboratory values and blood product transfusion. Multivariable analysis revealed that platelet transfusion was associated with 90-day mortality (OR: 1·05, P = 0·037) and one-year mortality for the entire cohort (OR = 1·05, P = 0·046,). Platelet transfusion volume was also associated with mortality in the VA-ECMO subset of patients at both 90 days (OR = 1·08, P = 0·03) and one year (OR: 1·11, P = 0·014). Age, peak International Normalized Raton ECMO, nadir haemoglobin (on ECMO) and final haemoglobin (after ECMO) were significantly associated with mortality for patients requiring VA-ECMO. For VV-ECMO patients, age, INR and peak creatinine on ECMO were associated with mortality. No individual component blood product was associated with one-year mortality for patients requiring VV-ECMO. Platelet transfusion was associated with increased 90-day and 1-year mortality for patients requiring VA-ECMO.
Sections du résumé
BACKGROUND
BACKGROUND
Studies examining one-year mortality respecting component blood transfusion are sparse. We hypothesize that component blood product transfusions are negatively associated with 90-day and 1-year survival for all patients requiring veno-arterial (VA) or veno-venous (VV) ECMO.
STUDY DESIGN AND METHODS
METHODS
This was an IRB-approved retrospective cohort analysis of 676 consecutive patients requiring ECMO at the University of Pittsburgh between 2005 and 2016. Patients were analysed both as an entire cohort and as two subsets with respect to ECMO modality (VA vs. VV). Additional data collected and analysed included patient characteristics, laboratory values and blood product transfusion.
RESULTS
RESULTS
Multivariable analysis revealed that platelet transfusion was associated with 90-day mortality (OR: 1·05, P = 0·037) and one-year mortality for the entire cohort (OR = 1·05, P = 0·046,). Platelet transfusion volume was also associated with mortality in the VA-ECMO subset of patients at both 90 days (OR = 1·08, P = 0·03) and one year (OR: 1·11, P = 0·014). Age, peak International Normalized Raton ECMO, nadir haemoglobin (on ECMO) and final haemoglobin (after ECMO) were significantly associated with mortality for patients requiring VA-ECMO. For VV-ECMO patients, age, INR and peak creatinine on ECMO were associated with mortality. No individual component blood product was associated with one-year mortality for patients requiring VV-ECMO.
CONCLUSION
CONCLUSIONS
Platelet transfusion was associated with increased 90-day and 1-year mortality for patients requiring VA-ECMO.
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
440-450Informations de copyright
© 2020 International Society of Blood Transfusion.
Références
Chen YS, Lin JW, Yu HY, et al.: Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 2008; 372:554-561
Combes A, Leprince P, Luyt CE, et al.: Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 2008; 36:1404-1411
Kelly RB, Porter PA, Meier AH, et al.: Duration of cardiopulmonary resuscitation before extracorporeal rescue: how long is not long enough? ASAIO J 2005; 51:665-667
Pagani FD, Aaronson KD, Swaniker F, et al.: The use of extracorporeal life support in adult patients with primary cardiac failure as a bridge to implantable left ventricular assist device. Ann Thorac Surg 2001; 71:S77-S81
Shin TG, Choi JH, Jo IJ, et al.: Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: A comparison with conventional cardiopulmonary resuscitation. Crit Care Med 2011; 39:1-7
Smedira NG, Blackstone EH: Postcardiotomy mechanical support: risk factors and outcomes. Ann Thorac Surg 2001; 71:S60-S66
Younger JG, Schreiner RJ, Swaniker F, et al.: Extracorporeal resuscitation of cardiac arrest. Acad Emerg Med 1999; 6:700-707
Massetti M, Tasle M, Le Page O, et al.: Back from irreversibility: extracorporeal life support for prolonged cardiac arrest. Ann Thorac Surg 2005; 79:178-183
Morris AH, Wallace CJ, Menlove RL, et al.: Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 149(2 Pt 1):295-305
Suchyta MR, Clemmer TP, Orme JF Jr, et al.: Increased survival of ARDS patients with severe hypoxemia (ECMO criteria). Chest 1991; 99:951-955
Esper SA, Bermudez C, Dueweke EJ, et al.: Extracorporeal membrane oxygenation support in acute coronary syndromes complicated by cardiogenic shock. Catheter Cardiovasc Interv 2015; 86(Suppl 1):S45-S50
Esper SA, Levy JH, Waters JH, et al.: Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anest Analg 2014; 118:731-743
Extracorporeal Life Support Organization (ELSO): ELSO patient specific guidelines, 2009; Website. Available at. Accessed August 1, 2012
Yeh TC, Chang HH, Ger LP, et al.: Clinical risk factors of extracorporeal membrane oxygenation support in older adults. PLoS One 2018; 13:e0195445
Rastan AJ, Dege A, Mohr M, et al.: Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg 2010; 139:302-311
Aubron C, Cheng AC, Pilcher D, et al.: Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. Critical Care 2013; 17:R73
ELSO: ELSO guidelines for cardiopulmonary extracorporeal life support, version 1.4. August 2017, 2017; www.elso.org, 2020
ELSO: ELSO Anticoagulation Guidelines, 2014; www.elso.org/Portals/0/Files/elsoanticoagulationguideline8-2014-table-contents.pdf. [Last accessed August 2020]
Agerstrand CL, Burkart KM, Abrams DC, et al.: Blood conservation in extracorporeal membrane oxygenation for acute respiratory distress syndrome. Ann Thorac Surg 2015; 99:590-595
ELSO: ELSO COVID-19 Interim Guidelines: A consensus document from an international group of Interdisciplinary ECMO providers, 2020; https://www.elso.org/Portals/0/Files/pdf/ELSO%20covid%20guidelines%20final.pdf. [Last accessed August 2, 2020]
Ang AL: Predictors of increased transfusion requirements and optimizing transfusional support in patients on Extracorporeal membrane oxygenation (ECMO). ISBT Sci Ser 2012; 7:89-91
Ang AL, Teo D, Lim CH, et al.: Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation - a single centre experience. Vox Sang 2009; 96:34-43
Butch SH, Knafl P, Oberman HA, et al.: Blood utilization in adult patients undergoing extracorporeal membrane oxygenated therapy. Transfusion 1996; 36:61-63
Chang WW, Tsai FC, Tsai TY, et al.: Predictors of mortality in patients successfully weaned from extracorporeal membrane oxygenation. PLoS One 2012; 7:e42687
Rastan AJ, Lachmann N, Walther T, et al.: Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs 2006; 29:1121-1131
Smith AH, Hardison DC, Bridges BC, et al.: Red blood cell transfusion volume and mortality among patients receiving extracorporeal membrane oxygenation. Perfusion 2013; 28:54-60
Benjamini YHY: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995; 57:12
Sut C, Tariket S, Aubron C, et al.: The Non-Hemostatic Aspects of Transfused Platelets. Front Med 2018; 5:42
Chen BZ, Xia R: Pro-inflammatory effects after platelet transfusion: a review. Vox Sang 2020; 115:349-357
Boudreau LH, Duchez AC, Cloutier N, et al.: Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 2014; 124:2173-2183
Inaba K, Branco BC, Rhee P, et al.: Impact of the duration of platelet storage in critically ill trauma patients. J Trauma Inj Infect Crit Care 2011; 71:1766-1774
Ming Y, Liu J, Zhang F, et al.: Transfusion of red blood cells, fresh frozen plasma, or platelets is associated with mortality and infection after cardiac surgery in a dose-dependent manner. Anest Analg 2020; 130:488-497
Cashen K, Dalton H, Reeder RW, et al.: Platelet transfusion practice and related outcomes in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2020; 21:178-185
Ong LP, Thompson E, Sachdeva A, et al.: Allogeneic blood transfusion in bilateral lung transplantation: impact on early function and mortality. Eur J Cardio Thorac Surg 2016; 49:668-674
de Boer MT, Christensen MC, Asmussen M, et al.: Impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008; 106:32-44
Spiess BD, Royston D, Levy JH, et al.: Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44:1143-1148
Karkouti K, Wijeysundera DN, Yau TM, et al.: Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Can J Anaesth 2006; 53:279-287
McGrath T, Koch CG, Xu M, et al.: Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes. Ann Thorac Surg 2008; 86:543-553
Kumar TK, Zurakowski D, Dalton H, et al.: Extracorporeal membrane oxygenation in postcardiotomy patients: factors influencing outcome. J Thorac Cardiovasc Surg 2010; 140:330-336
Lo Pinto H, Allyn J, Persichini R, et al.: Predictors of red blood cell transfusion and its association with prognosis in patients undergoing extracorporeal membrane oxygenation. Int J Artif Organs 2018; 41:644-652
Mazzeffi M, Greenwood J, Tanaka K, et al.: Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis. Ann Thorac Surg 2016; 101:682-689
Martucci G, Panarello G, Occhipinti G, et al.: Anticoagulation and transfusions management in veno-venous extracorporeal membrane oxygenation for acute respiratory distress syndrome: assessment of factors associated with transfusion requirements and mortality. J Intensive Care Med 2019; 34:630-639
Padmanabhan H, Brookes MJ, Nevill AM, et al.: Association between anemia and blood transfusion with long-term mortality after cardiac surgery. Ann Thorac Surg 2019; 108:687-692
Vivacqua A, Koch CG, Yousuf AM, et al.: Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg 2011; 91:1780-1790
LaPar DJ, Hawkins RB, McMurry TL, et al.: Preoperative anemia versus blood transfusion: which is the culprit for worse outcomes in cardiac surgery? J Thorac Cardiovasc Surg 2018; 156:66-74
Wu WC, Schifftner TL, Henderson WG, et al.: Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. J Am Med Assoc 2007; 297:2481-2488
Musallam KM, Tamim HM, Richards T, et al.: Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378:1396-1407
Swol J, Marschall C, Strauch JT, et al.: Hematocrit and impact of transfusion in patients receiving extracorporeal life support. Perfusion 2018; 33:546-552
Doyle AJ, Richardson C, Sanderson B, et al.: Restrictive transfusion practice in adults receiving venovenous extracorporeal membrane oxygenation: a single-center experience. Crit Care Explor 2020; 2:e0077
Oliver WC: Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13:154-175
Plotz FB, van Oeveren W, Bartlett RH, et al.: Blood activation during neonatal extracorporeal life support. J Thorac Cardiovasc Surg 1993; 105:823-832
Bolliger D, Szlam F, Molinaro RJ, et al.: Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009; 102:793-799